Recursion Pharmaceuticals has secured alignment with the FDA on a novel endpoint for its planned Phase III trial of REC-4881, an investigational treatment for familial adenomatous polyposis (FAP).

Speaking at the 2026 Jefferies Global Healthcare Conference in London on 18 November, Recursion’s CEO Najat Khan said the composite endpoint, which includes the excision of 10mm polyps could help capture the clinical benefits of the AI-enabled programme in a disease with a very high unmet need and patient burden and no approved therapies. The composite event-free survival measure is the study’s primary endpoint.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

REC-4881 is an oral MEK1/2 inhibitor being developed for FAP, a rare inherited disease caused by loss-of-function mutations in the APC gene. The condition is progressive and leads to the development of hundreds of precancerous polyps throughout the gastrointestinal (GI) tract, putting patients at significant risk of colorectal cancer.

“Polyps that are greater or equal to 10 millimeters are the ones that are known to have high risk of dysplasia and cancer,” Khan said. “It’s hard to remove them. There’s risk of perforation, bleeding, and often also incomplete removal of the polyp,” she added.

According to Khan, incorporating the novel component of polyp excisions into the composite endpoint is particularly important because removing larger polyps is already part of routine FAP treatment paradigm.

The randomised, placebo-controlled trial is expected to enrol approximately 200 adults with FAP who have previously undergone colectomy or proctocolectomy and is on track to begin in the second half of 2027.

FAP affects more than 50,000 people across the US and five major European markets, according to Recursion’s CEO. Patients typically undergo surgery to remove the colon to reduce their risk of colorectal cancer. However, polyps can continue developing in the remaining rectum, ileal pouch and upper GI tract, requiring repeated endoscopic surveillance and further interventions, highlighting the substantial burden of the disease.

“These patients are ‘going under’ for endoscopies and polyp removals, multiple times a year. So this is a highly, highly invasive, life-altering, and intensive disease,” Khan said.

Recursion’s AI capabilities

Recursion is seeking to demonstrate that its AI platform can repeatedly identify novel drug targets and develop differentiated medicines, with REC-4881’s planned Phase III trial representing a significant example.

Recursion is also using its artificial intelligence (AI) capabilities to inform the registrational study design. Khan said the company used natural history data and scraped approximately 256,000 physician notes covering around 1,000 patients to better understand disease progression and how FAP is currently managed.

The programme forms part of Recursion’s wider effort to demonstrate the clinical potential of its AI-enabled drug discovery platform, which has also produced the first-in-class oncology candidate REC-1245.

The company has additionally advanced partnered programmes with Sanofi and Roche.

Phase II data bolster pivotal trial plans

Recursion’s Phase III plans for REC-4881 follow updated results from its ongoing Phase Ib/II TUPELO study (NCT05552755), which demonstrated reductions in polyp burden across both the upper and lower GI tract.

Data presented earlier this month showed that 87% of patients experienced a reduction in total polyp burden after 12 weeks of treatment with REC-4881, with a median reduction of 47%. Approximately one-third of patients achieved reductions of at least 65%.

The effects also appeared durable, with 85% of evaluable patients remaining below their baseline polyp burden 12 weeks after stopping treatment. “Even when the patients are followed for three months off drug, most of the reduction is sustained,” Khan said.

Khan said the results were particularly encouraging in the upper GI tract, where removing polyps can be challenging because of the thin intestinal lining and associated risks of bleeding and perforation. The executive highlighted one patient case whose number of upper GI polyps measuring more than 5mm fell from 96 to just one following treatment. “That patient with over 96 polyps would have met the criteria for surgery. And with one polyp, they don’t meet the criteria for surgery,” Khan said. The company believes reducing polyp burden could translate into fewer surgical interventions, although this will need to be demonstrated in the pivotal study.